Prostatic Diseases D011469

Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Male » Prostatic Diseases

Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Genital Diseases, Male » Prostatic Diseases

Description

Pathological processes involving the PROSTATE or its component tissues.   MeSH

Subtype Terms (3)

Prostatic Hyperplasia
83 drugs (37 approved, 46 experimental)

Prostatic Neoplasms
971 drugs (358 approved, 613 experimental)

Prostatitis
40 drugs (27 approved, 13 experimental)


Phase 4 Indicated Drugs (2)

Phase 3 Indicated Drugs (1)

Phase 1 Indicated Drugs (2)

Other Experimental Indicated Drugs (3)


Organization Involved with Phase 4 Indications (2)

Organization Involved with Phase 1 Indications (1)

Organization Involved with Other Experimental Indications (3)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.